SCHEMBL22607015

SCHEMBL22607015

Bc1ccc(-c2nc(Cl)nc3ccccc23)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.71
ALDH1A1 P00352 4/20 0.71
LMNA P02545 3/20 0.51
MAPT P10636 3/20 0.51
ADORA2A P29274 4/20 0.47
NUDT1 P36639 3/20 0.47
HPGD P15428 2/20 0.47
GLA P06280 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
KMT2A Q03164 3/20 0.46
OPRK1 P41145 1/20 0.46
ATM Q13315 2/20 0.45
MEN1 O00255 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
GAA P10253 2/20 0.44
POLB P06746 1/20 0.44
MAPK1 P28482 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
NPSR1 Q6W5P4 1/20 0.42
MAOA P21397 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17286874 0.87 KDM4E (0.77) KDM4EALDH1A1LMNAMAPTADORA2A
SCHEMBL808191 0.87 KDM4E (0.77) KDM4EALDH1A1LMNAMAPTADORA2A
SCHEMBL808420 0.87 KDM4E (0.77) KDM4EALDH1A1LMNAMAPTADORA2A
SCHEMBL4087331 0.86 KDM4E (0.75) KDM4EALDH1A1LMNAMAPTADORA2A
Hydrochloric Acid SCHEMBL5803147 0.84 KDM4E (0.72) KDM4EALDH1A1LMNAMAPTADORA2A
SCHEMBL6329397 0.83 KDM4E (0.71) KDM4EALDH1A1LMNAMAPTADORA2A
SCHEMBL15860248 0.83 KDM4E (1.00) KDM4EALDH1A1LMNAMAPTADORA2A
SCHEMBL27711581 0.83 KDM4E (0.71) KDM4EALDH1A1LMNAMAPTADORA2A
SCHEMBL29423640 0.83 KDM4E (1.00) KDM4EALDH1A1LMNAMAPTADORA2A
SCHEMBL5803149 0.82 KDM4E (0.70) KDM4EALDH1A1LMNAMAPTADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11706982-B2 Fused polycyclic compound, and preparation method and use thereof NINGBO LUMILAN ADVANCED MATERIALS CO., LTD. (CN) 2023-07-18 US disclosed
US-20200343455-A1 Fused Polycyclic Compound, and Preparation Method and Use Thereof NINGBO LUMILAN ADVANCED MATERIALS, CO., LTD. (CN) 2020-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11706982-B2 Fused polycyclic compound, and preparation method and use thereof INF2, INTS9, PYM1 KDM4E 2744/4885ALDH1A1 3407/4885LMNA 413/4885
US-20200343455-A1 Fused Polycyclic Compound, and Preparation Method and Use Thereof INF2, INTS9, PYM1 KDM4E 2744/4885ALDH1A1 3407/4885LMNA 413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.